Open AccessA cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
Author(s) -
Giorgio Lorenzo Colombo,
S. Di Matteo,
Ketty Peris,
Maria Concetta Fargnoli,
Maria Esposito,
Annamaria Mazzotta,
Sergio Chimenti
Publication year - 2009
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s7348
Subject(s) - etanercept , psoriasis , medicine , dermatology , tumor necrosis factor alpha
Biologic therapies have proven efficacious for patients with moderate-to-severe psoriasis. However, their economic value compared with standard of care in Italy has not been explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic therapy in Italy.